Insigneo Advisory Services LLC Boosts Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Insigneo Advisory Services LLC grew its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 3.0% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 9,096 shares of the biopharmaceutical company’s stock after purchasing an additional 266 shares during the period. Insigneo Advisory Services LLC’s holdings in Gilead Sciences were worth $763,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of GILD. CarsonAllaria Wealth Management Ltd. raised its holdings in Gilead Sciences by 198.3% during the second quarter. CarsonAllaria Wealth Management Ltd. now owns 358 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 238 shares during the last quarter. nVerses Capital LLC purchased a new stake in shares of Gilead Sciences in the 3rd quarter worth about $25,000. Valued Wealth Advisors LLC increased its holdings in Gilead Sciences by 101.9% during the 3rd quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 161 shares in the last quarter. Cedar Wealth Management LLC lifted its holdings in shares of Gilead Sciences by 51.6% in the second quarter. Cedar Wealth Management LLC now owns 470 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 160 shares in the last quarter. Finally, Strategic Investment Solutions Inc. IL acquired a new stake in shares of Gilead Sciences in the second quarter valued at approximately $33,000. 83.67% of the stock is owned by hedge funds and other institutional investors.

Gilead Sciences Stock Down 1.3 %

Shares of NASDAQ:GILD opened at $92.13 on Friday. The stock has a 50-day simple moving average of $89.20 and a 200-day simple moving average of $78.64. The stock has a market capitalization of $114.82 billion, a P/E ratio of 1,023.67, a PEG ratio of 2.84 and a beta of 0.18. Gilead Sciences, Inc. has a 1 year low of $62.07 and a 1 year high of $98.90. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.10 and a current ratio of 1.26.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.58 by $0.44. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The company had revenue of $7.55 billion during the quarter, compared to the consensus estimate of $7.01 billion. During the same period in the previous year, the firm earned $2.29 earnings per share. Gilead Sciences’s revenue for the quarter was up 7.0% on a year-over-year basis. Equities analysts forecast that Gilead Sciences, Inc. will post 4.37 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 30th. Shareholders of record on Friday, December 13th will be given a $0.77 dividend. This represents a $3.08 annualized dividend and a yield of 3.34%. The ex-dividend date is Friday, December 13th. Gilead Sciences’s dividend payout ratio (DPR) is presently 3,422.22%.

Analyst Upgrades and Downgrades

GILD has been the subject of several research reports. Oppenheimer lifted their price objective on Gilead Sciences from $95.00 to $105.00 and gave the stock an “outperform” rating in a research report on Thursday, November 7th. Cantor Fitzgerald boosted their price target on Gilead Sciences from $70.00 to $80.00 and gave the stock a “neutral” rating in a report on Thursday, November 7th. The Goldman Sachs Group increased their price objective on Gilead Sciences from $74.00 to $84.00 and gave the company a “neutral” rating in a research note on Thursday, November 7th. Needham & Company LLC reiterated a “hold” rating on shares of Gilead Sciences in a research report on Thursday, November 7th. Finally, Leerink Partnrs upgraded shares of Gilead Sciences from a “hold” rating to a “strong-buy” rating in a report on Monday, October 21st. Twelve equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and four have given a strong buy rating to the company’s stock. Based on data from MarketBeat, Gilead Sciences has a consensus rating of “Moderate Buy” and a consensus price target of $95.41.

Insiders Place Their Bets

In other news, insider Merdad Parsey sold 164,211 shares of the company’s stock in a transaction on Wednesday, November 27th. The shares were sold at an average price of $91.92, for a total value of $15,094,275.12. Following the completion of the transaction, the insider now directly owns 80,801 shares in the company, valued at approximately $7,427,227.92. This represents a 67.02 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Andrew D. Dickinson sold 248,645 shares of Gilead Sciences stock in a transaction on Friday, November 29th. The stock was sold at an average price of $92.76, for a total transaction of $23,064,310.20. Following the sale, the chief financial officer now directly owns 138,919 shares in the company, valued at $12,886,126.44. This trade represents a 64.16 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 476,591 shares of company stock worth $43,747,615 over the last quarter. 0.16% of the stock is owned by corporate insiders.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.